No association of the CYP3A5*1 allele with blood pressure and left ventricular mass and geometry: the KORA/MONICA Augsburg echocardiographic substudy
Résumé
A polymorphism in the cytochrome-P450 3A (CYP3A) CYP3A5 enzyme has been implicated in blood pressure control and arterial hypertension. Carriers of the CYP3A5*1 allele show high while homozygous carriers of the CYP3A5*3 allele exhibit low CYP3A5 expression in the kidney, where CYP3A5 represents the major CYP3A enzyme. The aim of the current study was to investigate the association of the CYP3A5*1 allele with blood pressure, arterial hypertension, left ventricular (LV) mass and geometry in a large Caucasian population-based cohort. We compared blood pressure, LV mass measurements, and the prevalence of hypertension between carriers (CYP3A5*1/*1 and CYP3A5*1/*3 genotypes) and non-carriers (CYP3A5*3/*3 genotype) of the CYP3A5*1 allele in the echocardiographic substudy of the third MONICA (MONItoring trend and determinants in CArdiovascular disease) survey. After exclusion of 269 individuals on antihypertensive medications, 530 women and 554 men were available for analysis revealing allele frequencies of 5.8% and 94.2% for the CYP3A5*1 and CYP3A5*3 alleles, respectively. Overall, the presence of the CYP3A5*1 allele exhibited no effect on systolic and diastolic blood pressure in both genders. One third of the individuals of this cohort were hypertensive (blood pressures >140/90 mmHg) and the genotype distribution between normotensive and hypertensive individuals revealed after adjustment for age, BMI, and gender no association between CYP3A5*1 and hypertension (OR 1.02, p=0.92). Moreover, no effect of CYP3A5*1 on LV mass, wall thickness of the septal and posterior wall, and LV end-diastolic diameter was found. CYP3A5*1 exhibits no significant effect on blood pressure, LV mass and geometry in the MONICA echocardiographic substudy.
Origine : Fichiers produits par l'(les) auteur(s)
Loading...